141 related articles for article (PubMed ID: 28425810)
21. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
22. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans.
Vauquelin G; Fierens F; Van Liefde I
J Hypertens Suppl; 2006 Mar; 24(1):S23-30. PubMed ID: 16601569
[TBL] [Abstract][Full Text] [Related]
23. The inhibitory effect of KT3-671, a nonpeptide angiotensin-receptor antagonist, on rabbit and rat isolate vascular smooth muscles: a possible involvement of K(ATP) channels.
Satake N; Imanishi M; Keto Y; Ishikawa M; Yamada H; Shibata S; Tomiyama A
J Cardiovasc Pharmacol; 2000 Mar; 35(3):457-67. PubMed ID: 10710133
[TBL] [Abstract][Full Text] [Related]
24. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
Vauquelin G; Morsing P; Fierens FL; De Backer JP; Vanderheyden PM
Biochem Pharmacol; 2001 Feb; 61(3):277-84. PubMed ID: 11172731
[TBL] [Abstract][Full Text] [Related]
25. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological differences among angiotensin II receptor antagonists.
Belz GG
Blood Press Suppl; 2001; 2():13-8. PubMed ID: 11465912
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
Vanderheyden PM; Fierens FL; Vauquelin G
Biochem Pharmacol; 2000 Dec; 60(11):1557-63. PubMed ID: 11077037
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
[TBL] [Abstract][Full Text] [Related]
29. Involvement of the AT(2)-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):181-7. PubMed ID: 12563569
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of losartan and candesartan on vasoconstrictor responses in the rat.
Nossaman BD; Baber SR; Nazim MM; Detrolio JD; Kadowitz PJ
Can J Physiol Pharmacol; 2007; 85(3-4):360-71. PubMed ID: 17612645
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological properties of angiotensin II receptor antagonists.
Timmermans PB
Can J Cardiol; 1999 Nov; 15 Suppl F():26F-8F. PubMed ID: 10579749
[TBL] [Abstract][Full Text] [Related]
32. Different types of angiotensin II receptor antagonism induced by BIBS 222 in the rat portal vein and rabbit aorta; the influence of receptor reserve.
Zhang JS; Van Meel JC; Pfaffendorf M; Van Zwieten PA
J Pharmacol Exp Ther; 1994 May; 269(2):509-14. PubMed ID: 8182519
[TBL] [Abstract][Full Text] [Related]
33. Antagonist interaction with endogenous AT(1) receptors in human cell lines.
Verheijen I; Vanderheyden PM; De Backer JP; Bottari S; Vauquelin G
Biochem Pharmacol; 2002 Oct; 64(8):1207-14. PubMed ID: 12234601
[TBL] [Abstract][Full Text] [Related]
34. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
35. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
Belz GG; Breithaupt-Grögler K; Butzer R; Fuchs W; Hausdorf C; Mang C
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):336-41. PubMed ID: 11967820
[TBL] [Abstract][Full Text] [Related]
36. Pharmacology of AT1-receptor blockers.
Unger T
Blood Press Suppl; 2001; (3):5-10. PubMed ID: 11683476
[TBL] [Abstract][Full Text] [Related]
37. Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.
Failli P; Alfarano C; Franchi-Micheli S; Mannucci E; Cerbai E; Mugelli A; Raimondi L
Cardiovasc Diabetol; 2009 Jun; 8():32. PubMed ID: 19545435
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
Virone-Oddos A; Desangle V; Provost D; Cazes M; Caussade F; Cloarec A
Br J Pharmacol; 1997 Feb; 120(3):488-94. PubMed ID: 9031754
[TBL] [Abstract][Full Text] [Related]
40. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
